(062) Initial Cases in the U.S. With the AMS 700™ TENACIO™ Pump: Intra-operative Survey Results

Abstract Introduction There are over 1.7 million insured men with moderate to severe ED in the United States who could benefit from a penile implant. To continue to address this need, the TENACIO™ Pump was developed to provide improved tactile feedback and faster refill rate than predecessor inflatable penile prosthesis (IPP) pumps. New features include pump grips and a high profile deflation button (see Figure 1). The TENACIO Pump was FDA-approved in November 2023 and commercially available in June 2024. Objective To evaluate intra-operative surgeon experience and preferences with the TENACIO pump, regardless of patient presentation. Methods Implanting surgeons were surveyed following AMS 700™ cases involving a TENACIO Pump. Surveys assessed: -Clinical acceptability of new pump design features: clinically acceptable and preferred, clinically acceptable (preference not indicated), clinically acceptable and not preferred, or clinically unacceptable. -Physician satisfaction with the pump (1-5 Likert scale, not at all to very satisfied), and -Perspective on surgical placement and positioning (from a list of commercially available pumps). Results From June 10, 2024 to May 13, 2025, 203 surveys were completed by 27 implanters. Procedure count per respondent ranged from 1-22 (median 6 procedures). Clinical acceptability was high for the new pump grips, inflation mechanism, and deflation mechanism. For each of the features assessed by the survey, a majority of respondents preferred the TENACIO pump (Figure 2). Features with the highest clinical acceptance ratings were: palpating grips through the scrotum (78% preferred), stabilizing the pump (75% preferred), and palpating the deflation button (77% preferred). Ninety-five percent (95%) were either satisfied or very satisfied overall with the TENACIO Pump. The most common responses on performance regarding surgical placement and positioning in the scrotum, compared to other pumps, were “no preference” (53%) and the TENACIO Pump (40%), with 5% preferring the MS Pump, 2% preferring the Titan® Pump, and 0% preferring the Titan® Touch Pump. Conclusions Initial impressions from the intra-operative surgeon experience implanting the TENACIO Pump reflect high satisfaction with pump design features and clinical acceptability. Disclosure Yes, this is sponsored by industry/sponsor: Boston Scientific Corporation (BSC) Clarification: Industry initiated, executed and funded study Any of the authors act as a consultant, employee or shareholder of an industry for: BSC